← Back to Company DatabaseVisit Website
Myriad Genetics
Genetic testing for hereditary cancer risk and treatment guidance.
PublicSalt Lake City, UTFounded 1991
About
Myriad Genetics is a leading molecular diagnostics company offering genetic tests for hereditary cancer risk assessment and precision medicine. Its BRACAnalysis and myChoice CDx tests are widely used to guide treatment decisions for breast, ovarian, and other cancers. The company also provides tumor profiling and pharmacogenomics testing.
Total Funding
UndisclosedKey Product
BRACAnalysis hereditary cancer testGeography
North AmericaKey Investors
Public market investors
Focus Areas
DiagnosticsEarly Detection / Screening
Technology
Genomics / Sequencing
Cancer Types
BreastPan-cancerProstate
Last updated: Feb 4, 2026